W
WAVEMAN · COMPANY
RVMD · Revolution Medicines, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

RVMD

Revolution Medicines, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001628171
FORM 144 · 7☆ WATCH
INSIDER NET · 180D
-$90.9M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
488
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
17
codes C/M, not in net · $7.2M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$90.9M over 180 days
-$65.3M over 90 days
below 97% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
488 funds added or opened last quarter
more than 96% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$90.9M across 10 people in 180 days.
488 funds added or opened positions in the latest 13F quarter, of 703 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +431.3%
+431.3%12M
-1%+152%+306%+459%2025-092025-102025-122026-032026-052026-072026-09 2026-04-15 · GOLDSMITH MARK A sold $18.0M2026-06-15 · Horn Margaret A sold $9.7M2026-08-21 · GOLDSMITH MARK A sold $7.5M2026-08-21 · Cislini Jeff sold $5.4M2026-08-31 · Kim Lorence H. sold $5.3M2026-01-07 · Horn Margaret A sold $5.3M2026-08-21 · GOLDSMITH MARK A sold $5.2M2026-06-17 · Horn Margaret A sold $4.7M2025-11-25 · GOLDSMITH MARK A sold $4.5M2026-08-21 · Cislini Jeff sold $3.6M2026-08-31 · Kim Lorence H. sold $2.6M2025-09-11 · Kelsey Stephen Michael sold $2.5M2026-03-02 · GOLDSMITH MARK A sold $2.2M2026-01-07 · Horn Margaret A sold $2.1M2026-03-25 · Mancini Anthony sold $2.0M2025-09-11 · Kelsey Stephen Michael sold $1.9M2025-11-07 · GOLDSMITH MARK A sold $1.8M2026-06-24 · Anders Jack sold $1.6M2026-06-16 · GOLDSMITH MARK A sold $1.6M2026-08-31 · Kim Lorence H. sold $1.5M2025-11-18 · GOLDSMITH MARK A sold $1.4M2026-08-21 · GOLDSMITH MARK A sold $1.4M2026-08-31 · Kim Lorence H. sold $1.3M2025-11-12 · GOLDSMITH MARK A sold $1.3M2026-03-17 · GOLDSMITH MARK A sold $1.3M2025-10-13 · Kelsey Stephen Michael sold $1.2M2025-12-16 · GOLDSMITH MARK A sold $1.2M2025-09-15 · Kelsey Stephen Michael sold $1.1M2026-03-25 · Mancini Anthony sold $1.1M2026-08-21 · GOLDSMITH MARK A sold $1.1M2026-01-07 · Anders Jack sold $980.0K2026-06-24 · Anders Jack sold $956.4K2026-08-21 · Cislini Jeff sold $951.0K2025-11-18 · Cislini Jeff sold $939.0K2026-08-21 · GOLDSMITH MARK A sold $801.7K2026-08-21 · GOLDSMITH MARK A sold $767.9K2026-06-24 · Anders Jack sold $761.9K2026-06-16 · Mancini Anthony sold $720.5K2026-08-21 · Cislini Jeff sold $704.6K2026-08-21 · Cislini Jeff sold $702.8K2026-06-11 · Horn Margaret A sold $688.3K2025-10-17 · Cislini Jeff sold $660.0K2026-08-31 · Lorence H Kim filed to sell $15.2M2026-08-21 · JEFFREY TODD CISLINI filed to sell $16.1M2026-08-21 · MARK A GOLDSMITH filed to sell $16.9M2026-08-21 · THE REBECCA GOLDSMITH REVOCABLE TRUST filed to sell $635.2K2026-08-21 · THE JONATHAN GOLDSMITH REVOCABLE TRUST filed to sell $635.2K2026-06-29 · SUSHIL PATEL filed to sell $1.0M2026-06-24 · JACK ANDERS filed to sell $3.4M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $90.9M sold by insiders over 180 days, 488 funds added last quarter, $53.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Revolution Medicines, Inc. insiders sold a net $90.9M of stock across 324 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Kim Lorence H.
Director
SELL
2026-08-31
300.0
$60.2K
Kim Lorence H.
Director
SELL
2026-08-31
6,597.0
$1.3M
Kim Lorence H.
Director
SELL
2026-08-31
12,919.0
$2.6M
Kim Lorence H.
Director
SELL
2026-08-31
26,160.0
$5.3M
Kim Lorence H.
Director
SELL
2026-08-31
7,271.0
$1.5M
324 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 319 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
13,695,790.0 sh
$2.6B
FARALLON CAPITAL MANAGEMENT, L.L.C.
13,670,881.0 sh
$2.5B
FMR LLC
12,200,422.0 sh
$2.3B
BAKER BROS. ADVISORS LP
11,443,357.0 sh
$2.1B
Darwin Global Management, Ltd.
10,629,822.0 sh
$2.0B
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Lorence H Kim
FILED 2026-08-31
$15.2M
JEFFREY TODD CISLINI
FILED 2026-08-21
$16.1M
MARK A GOLDSMITH
FILED 2026-08-21
$16.9M
THE REBECCA GOLDSMITH REVOCABLE TRUST
FILED 2026-08-21
$635.2K
THE JONATHAN GOLDSMITH REVOCABLE TRUST
FILED 2026-08-21
$635.2K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
iShares Genomics Immunology and Healthcare ETF
$11.0M POSITION · AS OF 2026-04-30
6.9%
Tema Oncology ETF
$10.1M POSITION · AS OF 2026-02-28
6.3%
Marsico Midcap Growth Focus Fund
$21.3M POSITION · AS OF 2026-03-31
3.2%
Pinnacle Focused Opportunities ETF
$2.0M POSITION · AS OF 2026-02-28
3.2%
NICHOLAS PARTNERS SMALL CAP GROWTH FUND
$4.4M POSITION · AS OF 2026-03-31
3.0%
VanEck Biotech ETF
$10.6M POSITION · AS OF 2026-03-31
2.9%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 18 registered trials, 14 still enrolling or running — a status change here is dated weeks before the press release
4
Phase 1
3 ACTIVE
1
Phase 2
0 ACTIVE
6
Phase 3
6 ACTIVE
1
Not applicable
0 ACTIVE
6
Multi-phase
5 ACTIVE
What changed recently
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pan
2026-09-02 · Available → Approved For Marketing
—
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Dr. Goldsmith
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$14.7M
$37.1M
$4.5M
+101%
+25%
2024
$10.1M
$20.3M
$4.3M
+10%
+17%
2023
$10.4M
$14.0M
$3.8M
-28%
+14%
2022
$7.2M
$8.6M
$2.5M
-40%
+10%
2021
$7.8M
-$3.5M
$2.4M
-36%
+25%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$0$0$11.6M$35.4M
OPERATING INCOME$-1.2B$-689.5M$-487.2M$-258.3M
NET INCOME$-1.1B$-600.0M$-436.0M$-249.0M
EPS (DILUTED)-5.95-3.58-3.86-3.08
OPERATING CASH FLOW$-897.7M$-557.4M$-350.6M$-224.4M
CASH$383.7M$543.1M$696.1M$161.4M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →